Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Other Events
Item 8.01. Other Events.
On February 16, 2017, Global Blood Therapeutics, Inc. issued a
press release titled, Global Blood Therapeutics Announces
Initiation of Phase 1 Trial to Evaluate the Effect of GBT440 on
Oxygen Saturation in Healthy Volunteers (the Press Release). A
copy of the Press Release is filed herewith as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated February 16, 2017 |
About Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). Global Blood Therapeutics, Inc. (NASDAQ:GBT) Recent Trading Information
Global Blood Therapeutics, Inc. (NASDAQ:GBT) closed its last trading session up +1.95 at 26.90 with 1,632,331 shares trading hands.
